A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : 1,5-AG / 1,5-anhydroglucitol

[Related PubMed/MEDLINE]
Total Number of Papers: 98
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   1,5-AG  (>> Co-occurring Abbreviation)
Long Form:   1,5-anhydroglucitol
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2014 1,5-Anhydroglucitol and glycated albumin in glycemia. GA
2014 1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. ---
2014 Association of reduced levels of serum 1,5-Anhydro-d-glucitol with carotid atherosclerosis in patients with type 2 diabetes. IMT, PS
2014 Beyond HbA1c and Glucose: the Role of Nontraditional Glycemic Markers in Diabetes Diagnosis, Prognosis, and Management. HbA1c
2014 Change in urinary N-acetyl-beta-d-glucosaminidase levels relevant to postprandial glycemic control conditions in subjects without diabetes mellitus. DM
2014 Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus. GA
2014 Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy. DPP-4, DPP-4 inhibitor CTG, PPG, T2DM
2014 Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. CGM, L_RHI, RHI, T2DM
2014 Postprandial glycemic control conditions in relation to urinary N-acetyl-beta-D-glucosaminidase in patients with type 2 diabetes mellitus without low glomerular filtration rate. HbA1c, NAG
10  2014 Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study. AUC, DR, FPG, GA, HbA1c, PG, ROC
11  2014 [Indicators of glycemic control --hemoglobin A1c (HbA1c), glycated albumin (GA), and 1,5-anhydroglucitol (1,5-AG)]. AG, GA, NGSP
12  2013 1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus. CGMS, ROC
13  2013 1,5-Anhydroglucitol in diabetes mellitus. ---
14  2013 Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. BMI, MAGE, MDI, SMPG
15  2013 Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. 8-iso PGF2alpha, AUC-180, CGMS, CONGA, MAGE, MODD, MPMG
16  2013 Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus. AUC-180, CGMS, FA, HbA1c, MAGE, MAGEgos, MPMG
17  2013 Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. 75 g OGTT, CGMS, NAFLD, NASH, T2DM
18  2013 Protective effects of dietary 1,5-anhydro-D-glucitol as a blood glucose regulator in diabetes and metabolic syndrome. ---
19  2013 Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease. IMT, PI
20  2013 Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus. DM, UA
21  2012 A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China. ---
22  2012 Alternative markers of hyperglycemia and risk of diabetes. A1C, ARIC, HR
23  2012 Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. AUC
24  2012 Clinical and forensic examinations of glycemic marker 1,5-anhydroglucitol by means of high performance liquid chromatography tandem mass spectrometry. ---
25  2012 Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). AOC, AUC, BNP, CGM, CPR, GA, IRI, MAGE, PAI-1
26  2012 Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. T2D, VFA
27  2012 Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. HbA1c, T1D
28  2012 Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. CI, CSII, FA
29  2012 Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. SMC-DPP
30  2011 1,5-Anhydroglucitol levels are low irrespective of plasma glucose levels in patients with chronic liver disease. CLD
31  2011 A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. CGM, DPP-4, GIP, GLP-1
32  2011 Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. GLP-1, OHA
33  2011 Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. CGMS, FBG, GA, HbA1c, iAUC, LAGE, MAGE, MBG, MODD, PPGE, SDBG
34  2011 Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. 2h-PG, min, OGTTs, ROC
35  2011 Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. BIAsp 30, CAVI
36  2011 Nontraditional markers of glycemia: associations with microvascular conditions. ARIC
37  2011 Selective contribution of waist circumference reduction on the improvement of sleep-disordered breathing in patients hospitalized with type 2 diabetes mellitus. AHI, BMI, hs-CRP, SDB, T2DM, TBARS, WC
38  2011 Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. CHD, CVD, HRs
39  2011 The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. AUC, CGM, HbA1c
40  2011 [Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus]. GLP-1
41  2010 1,5-Anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions. IL, iNOS, LPS, MCP, TNF
42  2010 Habitual intake of dairy products influences serum 1,5-anhydroglucitol levels independently of plasma glucose. ---
43  2010 Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis. CFRD, IGT, OGTT
44  2010 Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). AG, CGM, CV, GA, SD
45  2010 Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes. FT1DM, T2DM
46  2009 Assessing postprandial glucose using 1,5-anhydroglucitol: An integrative literature review. PPHG
47  2009 Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system. ---
48  2009 Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. A1C, MPG
49  2008 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. ---
50  2008 A novel fully enzymatic method for determining glucose and 1,5-anhydro-D-glucitol in serum of one cuvette. GK
51  2008 Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. ---
52  2008 Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. HNF-1alpha, MODY, ROC
53  2008 Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients. alpha-GIs
54  2008 Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. BB, BMI, ITR-QOL, QOL
55  2008 Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry. ---
56  2008 Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. BIAsp 30, IGlar, PPG
57  2007 Hyperglycemia and diabetic renal change in a model of polyvinyl alcohol bioartificial pancreas transplantation. ---
58  2007 Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. DM
59  2007 Serum 1,5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. T1DM, T2DM
60  2006 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. AUC-180, CGMS, FA, MPMG
61  2006 Plasma anhydro-D-glucitol (1,5-AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes. MBG, MxG
62  2006 Short term intensive insulin therapy improves insulin secretion significantly in type 2 diabetic patients. AUCglucose, AUCinsulin
63  2005 Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. FFA, FPG, HDL
64  2005 The application of plasma 1,5-anhydro-D-glucitol for monitoring type 2 diabetic patients. FG, MBG, MxG
65  2004 Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. ---
66  2004 Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level. ACA, alpha-GIs, FPG, GC/MS, VOG
67  2004 Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. ---
68  2003 1,5-Anhydroglucitol stimulates insulin release in insulinoma cell lines. ---
69  2003 A novel NAD-dependent dehydrogenase, highly specific for 1,5-anhydro-D-glucitol, from Trichoderma longibrachiatum strain 11-3. AGH, SDS-PAGE
70  2003 Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. ---
71  2003 Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia. OGTT
72  2002 1,5-anhydro-D-glucitol: a novel marker of glucose excursions. FPG
73  2002 Clinical application of the serum 1,5-anhydroglucitol assay method using glucose 3-dehydrogenase. G3DH
74  2001 A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. ---
75  2001 Determination of 1,5-anhydro-D-glucitol on the basis of its inhibitory effect on trehalase activity. ---
76  2001 Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. IGT, OGTT
77  2000 The influence of traditional Chinese herbal drugs on serum 1, 5-anhydroglucitol levels. HbA1c, HPLC, Type 2 DM
78  2000 Transport of 1,5-anhydro-D-glucitol into insulinoma cells by a glucose-sensitive transport system. ---
79  1999 Economic evaluation of alternative indicators for screening for diabetes mellitus. AUCs, FRA, IGT, NIDDM
80  1999 Gas chromatographic-mass spectrometric analysis of urinary sugar and sugar alcohols during pregnancy. GC-MS
81  1999 Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. ---
82  1999 Serum concentration and renal handling of 1,5-anhydro-D-glucitol in patients with chronic renal failure. CRF, DM, FEAG, GTT
83  1998 Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. AUCinsulin, KITT
84  1998 Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients: possible application as a marker for vascular endothelial injury. Cr, NIDDM, TM, UAE
85  1998 Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. FPG, NAG
86  1996 1,5-anhydroglucitol as a marker for the differential diagnosis of acute and chronic renal failure. ARF, CRF
87  1996 Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. FPG, NIDDM
88  1996 Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-d-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy. ---
89  1996 Mannose, mannitol, fructose and 1,5-anhydroglucitol concentrations measured by gas chromatography/mass spectrometry in blood plasma of diabetic patients. DM
90  1996 Proteinuria and plasma hexosugars in early-stage glomerulonephritis. ---
91  1996 What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? DM, Fr, GA, HD
92  1995 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. FPG, NIDDM
93  1995 [Recent progress in diagnoses of diabetes and its complications]. AGE, GAD
94  1995 [Recent progress in evaluation of glycemic control by glycated protein and 1,5-AG]. AGE, DCCT
95  1994 Quantification of serum 1,5-anhydroglucitol in uremic and diabetic patients by liquid chromatography/mass spectrometry. LC/MS
96  1994 Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. ---
97  1989 Changes in relationship between blood glucose level and plasma 1,5-anhydroglucitol level in KK mice. ---
98  1986 Marked depletion of plasma 1,5-anhydroglucitol, a major polyol, in streptozocin-induced diabetes in rats and the effect of insulin treatment. STZ